Tumor vascular shutdown

Tumor vascular shutdown refers to the acute cessation or severe reduction of blood flow within established tumor vasculature, typically induced by therapeutic interventions such as vascular disrupting agents (VDAs), high-dose radiation therapy, or mechanobiology-based approaches like ultrasound-stimulated microbubbles. This process is not a single molecular target but rather a physiological outcome resulting from the action on multiple molecular targets—primarily proteins involved in maintaining endothelial cell structure and function. Mechanistically, VDAs can act by binding tubulin in proliferating endothelial cells lining immature tumor vessels, causing cytoskeletal collapse, increased permeability, exposure of pro-thrombotic surfaces, and ultimately thrombosis that leads to functional vessel occlusion. Some VDAs also induce apoptosis through cytokine-mediated pathways. High-dose radiation can similarly trigger acute vascular responses through ceramide-dependent apoptotic signaling. Clinically, this approach aims to starve tumors by cutting off their blood supply rapidly; however, mature vessels at the periphery are often resistant due to structural support from pericytes and smooth muscle cells. Imaging modalities such as perfusion MRI and targeted contrast-enhanced ultrasound are used for monitoring efficacy. Importantly, "tumor vascular shutdown" is not itself a canonical molecule or receptor but describes an effect achieved by targeting various molecules within the vasculature. Therefore it should not be considered a standard therapeutic target entity like an enzyme or receptor; rather it is an endpoint/process resulting from intervention with specific drugs or therapies[1][2][3].

Other names

Tumor vascular disruptionVascular disrupting agents (VDAs) effectTumor blood vessel disruption

Tubulin binding and microtubule depolymerization in endothelial cells leading to cytoskeletal collapse and increased permeability[1]; Induction of apoptosis in endothelial cells via cytokine production or ceramide-dependent signaling[1][2]; Exposure of basement membrane components resulting in platelet activation and thrombosis within tumor vessels[1]